Table 2 Detailed information for the individual drug of each arm in the PROSPECT study
Drug | BDQ | LFX | LZD | CS | CFZ | PZA | PTO |
|---|---|---|---|---|---|---|---|
BDQ-containing regimen (duration [weeks]) | X (24 to 40)a | X (40) | X (≥ 24) | X (40) | X (40) | ||
Non-BDQ-containing regimen (duration [weeks]) | NA | X (40) | X (≥ 24) | X (40) | X (40) | X (40) | X (First 16) |
Dosage formulation | Uncoated tablet | Film-coated tablet | Tablet | Capsule | Capsule | Tablet | Enteric-coated tablet |
Unit dose strength | 100 mg | 100 mg and 500 mg | 600 mg | 250 mg | 50 mg | 250 mg | 100 mg |
Dose regimen | 400 mg once daily for the first 2 weeks, 200 mg 3 times per week (with at least 48 h between doses) for the remaining weeks (i.e., 22 weeks or 38 weeks in case bedaquiline treatment is extended to 40 weeks) | 30–35 kg: 600 mg daily 36–55 kg: 750 mg daily > 55 kg: 1000 mg daily | 600 mg daily | 30–45 kg: 500 mg daily > 45 kg: 750 mg daily | 100 mg daily | 30–35 kg: 1000 mg daily 36–70 kg: 1500 mg daily > 70 kg: 2000 mg daily | 30–45 kg: 500 mg daily 46–70 kg: 600 mg daily > 70 kg: 800 mg daily |